Selected Publications
- A first-in-human Phase 1/2 clinical trial of SIRPalow activated macrophages (SIRPant-M) for the treatment of R/R-NHL. Koby Kidder, Rita N. Bárcia, Stephen Fogelson, Candida Fratazzi, Nathanael McCurley. SITC 2023
- VE303, an Oral Defined Bacterial Consortium, vs Placebo for the Prevention of Clostridioides difficile Infection: A Randomized Trial. Thomas Louie, MD, Candida Fratazzi, MD, et al. Jama in-press 2023.
- Precision Medicine: success stories and challenges from science to implementation. Attila Seyhan & Claudio Carini. The Era of Precision Health Care. Elsevier Pub Group in-press 2023.
- Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and strategies to improve response rates. Attila Seyhan & Claudio Carini. Int. J. Mol. Sci. 24, 41; 2023.
- Insights and strategies of Melanoma Immunotherapy. Attila Seyhan & Claudio Carini. Scholarly Community Encicopedia. Biopharmaceuticals Technology. https://encyclopedia.pub/entry/40614; 2023.
- Accelerated orphan drug approval: surrogate endpoints. C.Fratazzi and J Niu, W.J.A.P.M.R. 02(01), 001–007; 2022.
- Repurposing Drugs for Orphan Diseases. C. Fratazzi & J Niu. Acta Scientific Pharmacology 3: 1; 36-41: 2021.
- Eteplirsen Is Well Tolerated in Men With Mild or Moderate Renal Impairment. Candida Fratazzi, MD; Emily Naughton; Heidi Krenz. Sarepta Therapeutics, Inc., Cambridge, MA, USA. AIM 2019: 2019 Italian Myology Association. June 5–8, 2019. Bergamo, Italy
- Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome. David Dale, Frank Firkin, Audrey Anna Bolyard, Emily Dick, Sonja Hartmann, Karen Brown, Tarek Ebrahim, Candida Fratazzi, Sudha Parasuraman, Kenneth J. Gorelick. 60th Annual Meeting of the American Society for Hematology (ASH), December 2018, San Diego, California, USA.
- Chromosome conformation signatures response to methotrexate in early rheumatoid arthritis. Claudio Carini et Al. J. Transl. Med. 16:18, 2018.
- Immunogenicity of Biological Products: Current Perspectives and Future Implications. Candida Fratazzi, Attila Seyhan, Claudio Carini. Biosimilar
- Clinical Development: Scientific Considerations and New Methodologies. CRC Press 2016.
- Immunogenicity of Biological Products: Current Perspectives and Future Implications. C Fratazzi, A Seyhan, C Carini. Biosimilar Clinical Development: Scientific Considerations and New Methodologies, 71-84, Chapman and Hall/CRC, 2016/11/25
- Phase I/II, Nine Month Study Results of Enzyme Replacement Therapy with Gene Activated Human Glucocerebrosidase (GA-GCB) in Patients with Type I Gaucher Disease. Ari Zimran, MD, Candida Fratazzi et al. Blood 106 (11): 3882; 2005.
